Enovis Corporation (NYSE:ENOV – Get Free Report) insider Oliver Engert acquired 1,200 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were purchased at an average price of $21.62 per share, with a total value of $25,944.00. Following the acquisition, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Oliver Engert also recently made the following trade(s):
- On Wednesday, June 10th, Oliver Engert acquired 1,000 shares of Enovis stock. The shares were purchased at an average price of $23.00 per share, with a total value of $23,000.00.
- On Monday, June 1st, Oliver Engert acquired 1,000 shares of Enovis stock. The shares were purchased at an average price of $22.22 per share, with a total value of $22,220.00.
Enovis Trading Down 4.1%
NYSE ENOV traded down $0.89 during trading on Monday, reaching $20.91. 845,447 shares of the stock traded hands, compared to its average volume of 1,025,950. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -1.05 and a beta of 1.38. The stock’s 50-day moving average price is $24.00 and its 200 day moving average price is $24.50. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87. Enovis Corporation has a fifty-two week low of $20.55 and a fifty-two week high of $36.82.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC raised its position in Enovis by 12.5% during the first quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock worth $2,363,000 after acquiring an additional 7,072 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Enovis by 37.6% during the first quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock worth $10,226,000 after acquiring an additional 73,116 shares in the last quarter. Empowered Funds LLC raised its position in Enovis by 13.0% during the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after acquiring an additional 749 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after acquiring an additional 707 shares in the last quarter. Finally, Amundi raised its position in Enovis by 24,405.0% during the second quarter. Amundi now owns 9,802 shares of the company’s stock worth $328,000 after acquiring an additional 9,762 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.
Analyst Ratings Changes
ENOV has been the subject of several research analyst reports. Wall Street Zen cut shares of Enovis from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. Evercore reiterated an “outperform” rating and issued a $36.00 price target on shares of Enovis in a report on Friday, May 8th. Needham & Company LLC upped their price target on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a report on Thursday, February 26th. William Blair initiated coverage on shares of Enovis in a report on Friday, April 17th. They set an “outperform” rating for the company. Finally, Zacks Research cut shares of Enovis from a “strong-buy” rating to a “hold” rating in a report on Monday, June 1st. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $44.50.
Get Our Latest Analysis on Enovis
About Enovis
Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.
The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.
Read More
- Five stocks we like better than Enovis
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
